Skip to main content

Peer Review reports

From: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis

Original Submission
6 Sep 2021 Submitted Original manuscript
16 Oct 2021 Reviewed Reviewer Report
16 Nov 2021 Reviewed Reviewer Report
1 Dec 2021 Author responded Author comments - Xiaohua Hou
Resubmission - Version 2
1 Dec 2021 Submitted Manuscript version 2
9 Dec 2021 Author responded Author comments - Xiaohua Hou
Resubmission - Version 3
9 Dec 2021 Submitted Manuscript version 3
18 Dec 2021 Author responded Author comments - Xiaohua Hou
Resubmission - Version 4
18 Dec 2021 Submitted Manuscript version 4
6 Jan 2022 Reviewed Reviewer Report
7 Jan 2022 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
7 Jan 2022 Editorially accepted
21 Jan 2022 Article published 10.1186/s12876-022-02101-7

You can find further information about peer review here.

Back to article page